ALL

Conference Coverage

Predicting outcomes of allo-HSCT in ALL

Photo by Chad McNeeley SAN DIEGO—A retrospective study has revealed a few factors that may predict outcomes of allogeneic hematopoietic stem cell...

News

Fusion protein fights resistant ALL

In a preclinical study, a fusion protein targeted treatment-resistant leukemia, demonstrating superiority over both chemotherapy and radiation....

News

EC supports continued use of ponatinib

Credit: Rhoda Baer The European Commission (EC) has concluded that ponatinib (Iclusig) should continue to be prescribed in accordance with its...

Conference Coverage

CARs come in different makes and models

Credit: NIAID SAN FRANCISCO—CTL019, a chimeric antigen receptor (CAR) T cell targeting CD19, is not the only CAR in the production line....

Conference Coverage

CAR produces durable responses in B-cell ALL

Credit: Charles Haymond SAN FRANCISCO—JCAR015, a chimeric antigen receptor (CAR) T-cell therapy, can produce durable responses in patients with B...

Conference Coverage

CAR-T cell therapy rolls on in pediatric ALL

Key clinical point: CAR-T cell therapy continues to provide durable responses in early studies of children with refractory ALL. Major finding:...

Pages